Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD

Blood (2019) 134 (Supplement_1): 3148.

https://doi.org/10.1182/blood-2019-131400

Published: 2019

Journal Articles

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Bhumika J. Patel, MD, Madeline Waldron, PharmD, Jackie Tomer, MPH, Roman Goldman, CNP, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Saveta Mathur, CNP, Christy J. Samaras, DO, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2018-99-119979

Published: 2018

Journal Articles

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Jack Khouri, MD, Thapa Bicky, MD, Frederic J. Reu, MD, Christy J. Samaras, DO, Hien D. Liu, MD, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 1819.

https://doi.org/10.1182/blood.V130.Suppl_1.1819.1819

Published: 2017

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

Response Adapted Induction Therapy for Multiple Myeloma

Jason Valent, MD, Christy Samaras, DO, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Brian J. Bolwell, MD, Janice Reed, RN, Mary Ann Karam, RN, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Mitchell R. Smith, MD PhD, Hien K. Liu, MD, Frederic J Reu

Blood (2015) 126 (23): 3327.

https://doi.org/10.1182/blood.V126.23.3327.3327

Published: 2015

Journal Articles

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Mayur Narkhede, MD, Jason Valent, MD, Chad Cummings, MBA, Katherine Glass, MPH, MS, Debbie Hastings, Beth Faiman, PhD, CNP, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt E. Kalaycio, MD, Brian J. Bolwell, MD, Mitchell R. Smith, MD PhD, Hien K. Duong, MD, Christy Samaras, DO, Frederic J. Reu, MD

Blood (2014) 124 (21): 2620.

https://doi.org/10.1182/blood.V124.21.2620.2620

Published: 2014

Journal Articles

A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Leonard J. Horwitz, MD, Beth Faiman, CNP, Paul Elson, ScD, Rachid Baz, MD, Mohamad Hussein, MD, John A Lust, MD, PhD, Paulette Mehta, MD, MPH, Frederic J. Reu, MD, Becky Habecker, Janice Reed, RN, Mary Ann Karam, RN, Robert M Dean, MD, Ronald Sobecks, MD, Eric D. Hsi, MD, Varsha Kaushal, MD, Matt Kalaycio, MD

Blood (2012) 120 (21): 5045.

https://doi.org/10.1182/blood.V120.21.5045.5045

Published: 2012

Journal Articles

Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study

Frederic J. Reu, MD, Shahper N Khan, PhD, Reda Z Mahfouz, MD/PhD, Robert M Dean, MD, Beth Faiman, CNP, Janice Reed, RN, Mary Ann Karam, RN, Kimberly Hamilton, RN, Sherry Fada, Matt Kalaycio, MD, Erica L. Campagnaro, MD, Tamila L. Kindwall-Keller, DO, Jason Valent, M.D., Christy Samaras, DO, Ronald Sobecks, MD, Carolyn Jirousek, R. N., Hien K. Duong, MD, Mohammed Orloff, Ph.D., Yogen Saunthararajah, MD

Blood (2012) 120 (21): 5031.

https://doi.org/10.1182/blood.V120.21.5031.5031

Published: 2012

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).

Khaldoun Almhanna, MD, MPH, Revathi Suppiah, MD, Rachid Baz, MD, Mary Ann Karam, Beth Faiman, CNP, MSN, Janice Reed, RN, Mohamad Hussein, MD

Blood (2005) 106 (11): 2557.

https://doi.org/10.1182/blood.V106.11.2557.2557

Published: 2005

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD

Blood (2004) 104 (11): 208.

https://doi.org/10.1182/blood.V104.11.208.208

Published: 2004

Journal Articles

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Rony M. Abou-Jawde, MD, Janice Reed, RN, Megan Kelly, Luba Platt, BS, Mary Ann Karam, RN, Mary Ruth Kovak, MSN, MBA, Gordan Srkalovic, MD, PhD, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 2419.

https://doi.org/10.1182/blood.V104.11.2419.2419

Published: 2004

Journal Articles

Bisphosphonate Therapy Associated with an Increased Incidence of Mandibular/Maxillary Osteomyelitis in Multiple Myeloma Patients.

Snehal G. Thakkar, MD, Carlos Isada, MD, Kristin Englund, MD, Walter Tomford, MD, Mary Ann Karam, RN, Janice L. Reed, RN, James Smith, DDS, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 4925.

https://doi.org/10.1182/blood.V104.11.4925.4925

Published: 2004

NARROW

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Response-Adapted Therapy for Newly Diagnosed Myeloma

Response Adapted Induction Therapy for Multiple Myeloma

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Bisphosphonate Therapy Associated with an Increased Incidence of Mandibular/Maxillary Osteomyelitis in Multiple Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only